Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
8
×
fda
8
×
indiana blog main
indiana top stories
life sciences
medicare
8
×
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
eli lilly
clinical trials
scott gottlieb
amgen
biogen
bristol-myers squibb
cancer
celgene
donald trump
drug prices
gene therapy
What
bio
roundup
drug
alzheimer’s
annual
cancer
drugs
fallout
ipo
notes
price
prices
thanks
trump
week
administration
afternoon
airport
allogene
angry
anti
anticipated
apocalypse
appetite
arena’s
assessed
attention
awaited
beds
benefited
biotech
black
blueprint
bounty
bread
butter
buyout
cash
celgene
cig
Language
Current search:
medicare
×
fda
×
" detroit top stories "
×
@xconomy.com
5 years ago
Losing “Scalps”? Despite Pharma Fear, A Split on Trump Rx-Price Plans
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
Trump Pledges Lower Drug Prices, But Blueprint Is Short on Details